Li-Zhen Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li-Zhen Dai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chen-Shi Lin
Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, China
4 shared publications - Hong Ma
Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
4 shared publications - Shu-Yuan Liu
Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
2 shared publications - Yanling Huang
Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
2 shared publications - Yu-Hao Lin
Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China
2 shared publications Danling Chen
Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, China
1 shared publication
Latest Publications
- Open Access
- 28 November 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (11)
A Case of Pseudohypoparathyroidism Misdiagnosed as Idiopathic Epilepsy for 5 Years: Clinical Analysis and Follow-up Outcomes
We report a 15-year-old Chinese girl who presented with intermittent seizure episodes and had been misdiagnosed as having idiopathic epilepsy 5 years previously. Laboratory testing revealed hypocalcemia, hyperphosphatemia, and a high parathyroid hormone (PTH) concentration. She was subsequently shown to have pseudohypoparathyroidism type Ib (PHPIb) based on the results of methylation analysis of the GNAS gene, which showed a loss of methylation of the differentially methylated regions (DMR) of GNAS-AS1, GNAS-XL, and GNAS-A/B; and a gain of methylation of the DMR of the GNAS-NESP55 region. We adjusted the patient’s medication by prescribing calcium and calcitriol supplements, and gradually reduced the doses of antiepileptic drugs, until they had been completely discontinued. As a result, the patient did not experience any further seizures or epileptiform symptoms; and had normal plasma calcium, phosphorus, and 25-hydroxyvitamin D concentrations and 24-hour urinary calcium excretion. In addition, her PTH concentration gradually normalized over 12 months, and no urinary stones were found on ultrasonographic examination. In conclusion, the clinical presentation of PHP is complex, and the condition is often misdiagnosed. The diagnosis and follow-up of the present patient have provide valuable insights that should contribute to informed clinical decision-making and the implementation of appropriate treatment strategies.
- 28 November 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (11)
Open AccessA Case of Pseudohypoparathyroidism Misdiagnosed as Idiopathic Epilepsy for 5 Years: Clinical Analysis and Follow-up Outcomes
We report a 15-year-old Chinese girl who presented with intermittent seizure episodes and had been misdiagnosed as having idiopathic epilepsy 5 years previously. Laboratory testing revealed hypocalcemia, hyperphosphatemia, and a high parathyroid hormone (PTH) concentration. She was subsequently shown to have pseudohypoparathyroidism type Ib (PHPIb) based on the results of methylation analysis of the GNAS gene, which showed a loss of methylation of the differentially methylated regions (DMR) of GNAS-AS1, GNAS-XL, and GNAS-A/B; and a gain of methylation of the DMR of the GNAS-NESP55 region. We adjusted the patient’s medication by prescribing calcium and calcitriol supplements, and gradually reduced the doses of antiepileptic drugs, until they had been completely discontinued. As a result, the patient did not experience any further seizures or epileptiform symptoms; and had normal plasma calcium, phosphorus, and 25-hydroxyvitamin D concentrations and 24-hour urinary calcium excretion. In addition, her PTH concentration gradually normalized over 12 months, and no urinary stones were found on ultrasonographic examination. In conclusion, the clinical presentation of PHP is complex, and the condition is often misdiagnosed. The diagnosis and follow-up of the present patient have provide valuable insights that should contribute to informed clinical decision-making and the implementation of appropriate treatment strategies.
- Open Access
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to 16 January 2022. The efficacy outcomes were the changes of body weight, glucose level and blood pressure. The safety outcomes were serious adverse events and discontinuation due to adverse events. The mean differences, ORs, 95% credible intervals (95% CI), the surface under the cumulative ranking were evaluated for each outcome by network meta-analysis. Results Sixty-one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% wt loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: −0.39%, 95% CI −0.70 to −0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4 mg was among the most effective interventions in losing body weight (MD: −11.51 kg, 95% CI −12.83 to −10.21), decreasing HbA1c (MD: −1.49%, 95% CI −2.07 to −0.92) and fasting plasma glucose (MD: −2.15 mmol/L, 95% CI −2.83 to −1.59), reducing systolic blood pressure (MD: −4.89 mm Hg, 95% CI −6.04 to −3.71) and diastolic blood pressure (MD: −1.59 mm Hg, 95% CI −2.37 to −0.86) with moderate certainty evidences, while it was associated with high risk of adverse events. Conclusions Semaglutide 2.4 mg showed the greatest effects on losing body weight, controlling glycaemic level and reducing blood pressure while it was associated with high risk of adverse events. PROSPERO registration number CRD42021258103.
Open AccessEfficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to 16 January 2022. The efficacy outcomes were the changes of body weight, glucose level and blood pressure. The safety outcomes were serious adverse events and discontinuation due to adverse events. The mean differences, ORs, 95% credible intervals (95% CI), the surface under the cumulative ranking were evaluated for each outcome by network meta-analysis. Results Sixty-one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% wt loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: −0.39%, 95% CI −0.70 to −0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4 mg was among the most effective interventions in losing body weight (MD: −11.51 kg, 95% CI −12.83 to −10.21), decreasing HbA1c (MD: −1.49%, 95% CI −2.07 to −0.92) and fasting plasma glucose (MD: −2.15 mmol/L, 95% CI −2.83 to −1.59), reducing systolic blood pressure (MD: −4.89 mm Hg, 95% CI −6.04 to −3.71) and diastolic blood pressure (MD: −1.59 mm Hg, 95% CI −2.37 to −0.86) with moderate certainty evidences, while it was associated with high risk of adverse events. Conclusions Semaglutide 2.4 mg showed the greatest effects on losing body weight, controlling glycaemic level and reducing blood pressure while it was associated with high risk of adverse events. PROSPERO registration number CRD42021258103.
- Open Access
- 21 September 2022
- Published by SAGE Publications in Women's Health
- Vol. 18
A rare case of 17α-hydroxylase/17, 20-lyase deficiency: Clinical and genetic findings and follow-up outcomes
Here, we reported a case of a 16-year-old Chinese female patient (46, XX) diagnosed as 17α-hydroxylase/17, 20-lyase deficiency (17-OHD) in June 2018 and over 3 years follow-up outcomes; 17-OHD is a rare form of congenital adrenal hyperplasia. The patient presented with primary amenorrhea, underdeveloped secondary sexual characteristics, hypertension and hypokalemia. Hormonal findings revealed decreased estrogen and androgen, increased progesterone, low cortisol concentration and compensatory high adrenocorticotropic hormone level. Mutation analysis of the CYP17A1 gene identified the c.1459_1467del GACTCTTTC homozygous deletion in exon 8, namely, D487_F489del mutation, resulting in the deletion of Aspartate–Serine–Phenylalanine amino acids. The patient’s father and mother were all heterozygous carriers of this mutation. The diagnosis and follow-up outcomes provided useful insights to support clinical decision-making and appropriate treatment.
- 21 September 2022
- Published by SAGE Publications in Women's Health
- Vol. 18
Open AccessA rare case of 17α-hydroxylase/17, 20-lyase deficiency: Clinical and genetic findings and follow-up outcomes
Here, we reported a case of a 16-year-old Chinese female patient (46, XX) diagnosed as 17α-hydroxylase/17, 20-lyase deficiency (17-OHD) in June 2018 and over 3 years follow-up outcomes; 17-OHD is a rare form of congenital adrenal hyperplasia. The patient presented with primary amenorrhea, underdeveloped secondary sexual characteristics, hypertension and hypokalemia. Hormonal findings revealed decreased estrogen and androgen, increased progesterone, low cortisol concentration and compensatory high adrenocorticotropic hormone level. Mutation analysis of the CYP17A1 gene identified the c.1459_1467del GACTCTTTC homozygous deletion in exon 8, namely, D487_F489del mutation, resulting in the deletion of Aspartate–Serine–Phenylalanine amino acids. The patient’s father and mother were all heterozygous carriers of this mutation. The diagnosis and follow-up outcomes provided useful insights to support clinical decision-making and appropriate treatment.
- Open Access
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to Jan 16, 2022. The efficacy outcomes were the changes of body weight, glycemic control and blood pressure. The safety outcomes were the serious adverse events and discontinuation due to adverse events. The mean differences (MDs), odds ratios (ORs), 95% credible intervals (95% CI), the surface under the cumulative ranking (SUCRA) were evaluated for each outcome by network meta-analysis. Results Sixty one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% weight loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: -0.39%, 95% CI: -0.70 to -0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4mg was the most efficacious agent in losing body weight (MD: -11.51kg, 95% CI: -12.83 to -10.21, SUCRA: 0.99), decreasing HbA1c (MD: -1.49%, 95% CI: -2.07 to -0.92, SUCRA: 0.93), fasting plasma glucose (MD: -2.15mmol/L, 95% CI: -2.83 to -1.59, SUCRA: 0.92), reducing systolic blood pressure (MD: -4.89mmHg, 95% CI: -6.04 to -3.71, SUCRA: 0.96), diastolic blood pressure (MD: -1.59mmHg, 95% CI: -2.37 to -0.86) while it was associated with high risk of adverse events. Conclusions Semaglutide 2.4mg showed greatest effects on losing body weight, controlling glycemic level and reducing blood pressure while it was associated with high risk of adverse events. Strengths and limitations of this study ▸ Different types of GLP-1RAs and SGLT-2is in overweight/obese patients with or without diabetes mellitus were compared and analyzed in the study. ▸ In the absence of direct ‘head-to-head’ comparisons of GLP-1RAs and SGLT-2is in overweight or obese adults with or without diabetes mellitus, network meta-analysis was performed to compare the efficacy and safety of the drugs. ▸ The efficacy and safety between different dose of liraglutide and semaglutide was compared and analyzed in the study. ▸ Limitation of this study was that the numbers of RCTs included were few in some comparisons.
Open AccessEfficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to Jan 16, 2022. The efficacy outcomes were the changes of body weight, glycemic control and blood pressure. The safety outcomes were the serious adverse events and discontinuation due to adverse events. The mean differences (MDs), odds ratios (ORs), 95% credible intervals (95% CI), the surface under the cumulative ranking (SUCRA) were evaluated for each outcome by network meta-analysis. Results Sixty one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% weight loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: -0.39%, 95% CI: -0.70 to -0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4mg was the most efficacious agent in losing body weight (MD: -11.51kg, 95% CI: -12.83 to -10.21, SUCRA: 0.99), decreasing HbA1c (MD: -1.49%, 95% CI: -2.07 to -0.92, SUCRA: 0.93), fasting plasma glucose (MD: -2.15mmol/L, 95% CI: -2.83 to -1.59, SUCRA: 0.92), reducing systolic blood pressure (MD: -4.89mmHg, 95% CI: -6.04 to -3.71, SUCRA: 0.96), diastolic blood pressure (MD: -1.59mmHg, 95% CI: -2.37 to -0.86) while it was associated with high risk of adverse events. Conclusions Semaglutide 2.4mg showed greatest effects on losing body weight, controlling glycemic level and reducing blood pressure while it was associated with high risk of adverse events. Strengths and limitations of this study ▸ Different types of GLP-1RAs and SGLT-2is in overweight/obese patients with or without diabetes mellitus were compared and analyzed in the study. ▸ In the absence of direct ‘head-to-head’ comparisons of GLP-1RAs and SGLT-2is in overweight or obese adults with or without diabetes mellitus, network meta-analysis was performed to compare the efficacy and safety of the drugs. ▸ The efficacy and safety between different dose of liraglutide and semaglutide was compared and analyzed in the study. ▸ Limitation of this study was that the numbers of RCTs included were few in some comparisons.